A randomized, multicentre, double blind, placebo-controlled trial of anti TNF alpha (adalimumab) in refractory hand osteoarthritis. The Dora study - Université de Lorraine Access content directly
Conference Papers Year : 2013

A randomized, multicentre, double blind, placebo-controlled trial of anti TNF alpha (adalimumab) in refractory hand osteoarthritis. The Dora study

Dates and versions

hal-01509629 , version 1 (18-04-2017)

Identifiers

Cite

X. Chevalier, P. Ravaud, E. Maheu, G. Baron, A. Rialland, et al.. A randomized, multicentre, double blind, placebo-controlled trial of anti TNF alpha (adalimumab) in refractory hand osteoarthritis. The Dora study. 2013 OARSI World Congress, Apr 2013, Philadelphie, United States. ⟨10.1016/j.joca.2013.02.311⟩. ⟨hal-01509629⟩
86 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More